Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
Jorge Polanco
Border 'emergency'
Haiti
Daytona 500
Smoking ban
Bad candy
India
Fire starter
UPS hijacked
Storm deaths
Food banks
Student loans
'Snowna Lisa'
Health News
Feb. 8, 2019 / 9:20 AM

'Trojan horse' cancer drug brings hope against tumors

By
Tauren Dyson
Nearly 15 percent of patients with ovarian and lung cancer either had their tumors shrink or stop growing after taking tisotumab vedotin. Photo by toeytoey/Shutterstock

Feb. 8 (UPI) -- A new "trojan horse" approach to treating cancer has shown promise in its first clinical trial run, a new study says.

Nearly 15 percent of patients with ovarian and lung cancer either had their tumors shrink or stop growing after taking tisotumab vedotin, or TV, according to a study published Thursday in The Lancet Oncology.

"What is so exciting about this treatment is that its mechanism of action is completely novel -- it acts like a Trojan horse to sneak into cancer cells and kill them from the inside," Johann de Bono, a researcher Regius Professor of Cancer Research at The Institute of Cancer Research and study author, said in a news release. "Our early study shows that it has the potential to treat a large number of different types of cancer, and particularly some of those with very poor survival rates."

As the name suggests, TV kills cancer cells from within by leaking out a toxic substance.

RELATED Immunotherapy effective for cancer patients with HIV

Of the other patients who showed positive responses after taking TV, 27 percent had bladder cancer, 26.5 percent had cervical cancer, 14 percent had ovarian cancer, 13 percent had esophageal, 13 percent had non-small cell lung and 7 percent had endometrial cancer.

On average, those results lasted between 5.7 months and 9.5 months for some patients in the study. The treatments did, however, lead to nose bleeds, fatigue, nausea and eye problems in some patients.

"TV has manageable side effects, and we saw some good responses in the patients in our trial, all of whom had late-stage cancer that had been heavily pre-treated with other drugs and who had run out of other options," de Bono said. "We have already begun additional trials of this new drug in different tumor types and as a second-line treatment for cervical cancer, where response rates were particularly high. We are also developing a test to pick out the patients most likely to respond."

RELATED HPV linked to increased risk for cardiovascular disease

Researchers are now testing TV in trials with other cancers like bowel, pancreatic, squamous cell lung and head and neck. They're also giving it another trial run at cervical cancer.

"It's exciting to see the potential shown by TV across a range of hard-to-treat cancers. I look forward to seeing it progress in the clinic and hope it can benefit patients who currently have run out of treatment options," said Paul Workman, chief executive and professor at The Institute of Cancer Research.

RELATED Benign ovarian cysts should not be removed, study suggests
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Post-menopausal women who drink diet soda have increased stroke risk
Irregular heartbeat triggers can easily be altered
Timing of DDT exposure can affect chance for breast cancer
CDC: Flu shot much more effective this year
People with sleep apnea three times as likely to have heart failure

Photo Gallery

 
Balloons take flight at Al-Ula Balloon Festival in Saudi Arabia

Latest News

Judge issues gag order in Roger Stone case
Mueller interviewed Sanders in Russia probe
Acacia ants' vibrational sensors can differentiate between nibbles and wind
Study: Chemical in Roundup may increase cancer risk by 40 percent
Aurora, Ill., shooting leaves one dead
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy